Antibiotic conjugates directly linked with steroid drugs

Patent metadata

Field	Value
Publication number	US-9402912-B2
Application number	US-201414198939-A
Country	US
Kind code	B2
Filing date	Mar 6, 2014
Priority date	Mar 8, 2013
Publication date	Aug 2, 2016
Grant date	Aug 2, 2016

Abstract

The present invention describes novel single drug entities, formed by direct linkage of an antibiotic to a steroidal drug. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. The antibiotic is coupled directly to the steroid drug.

First claim

What is claimed is:

1. A hybrid drug comprising one antibiotic moiety and one steroid moiety, or a pharmaceutical salt thereof, which are connected covalently via a linker, wherein the bond is an ester bond or an amide bond, and wherein the antibiotic moiety is a gatifloxacin moiety and the steroid moiety is a prednisolone moiety.

2. The hybrid drug of claim 1 , having the following structure:

or a pharmaceutically acceptable salt thereof.

3. The hybrid drug of claim 2 , wherein the pharmaceutically acceptable salt is a fumarate salt.

4. A method comprising administrating to an eye of a mammal a pharmaceutical composition comprising a therapeutically active amount of a hybrid drug of any one of claims 1 - 3 , wherein said method is effective in the treatment of a bacterial infection or an inflammation affecting said eye.

5. The method according to claim 4 , wherein the method is effective in the treatment of conjunctivitis, keratitis, blepharitis, dacryocystitis, hordeolum, corneal ulcers, anterior blepharitis, posterior blepharitis, endophthalmitis, meibomian gland dysfunction, dry eye disease, ocular pain, ocular pain and inflammation post-ocular surgery, bacterial conjunctivitis, anterior uveitis, post-surgical inflammation, inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, allergic conjunctivitis, ocular rosacea, blepharitis, meibomian gland dysfunction, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis, corneal injury from chemical radiation, or thermal burns, penetration of foreign bodies or allergy.

6. The method according to claim 4 , wherein the mammal is a human.

7. A pharmaceutical composition comprising a hybrid drug of claim 1 in a pharmaceutically acceptable carrier.

8. The hybrid drug of claim 1 , wherein the covalent bond is an ester bond.

9. The pharmaceutical composition of claim 7 , wherein said pharmaceutical composition is formulated for topical ophthalmic administration.

Assignees

• Allergan Inc

Inventors

• Sinha Santosh C
• Chow Ken
• Wang Liming
• Garst Michael E
• Attar Mayssa
• Swift Brandon D

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P31/02

  Local antiseptics · CPC title

• A61P27/02

  Ophthalmic agents · CPC title